TALS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TALS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-05), Talaris Therapeutics's Beta is Not available.
The historical data trend for Talaris Therapeutics's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Talaris Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Beta | - | - | - | - |
Talaris Therapeutics Quarterly Data | |||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Beta | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Talaris Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's Beta distribution charts can be found below:
* The bar in red indicates where Talaris Therapeutics's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Talaris Therapeutics (NAS:TALS) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Thank you for viewing the detailed overview of Talaris Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.
Cariad Chester | director | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Yung H. Chyung | officer: Chief Medical Officer | C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139 |
Caley Castelein | director | THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104 |
W Bradford Middlekauff | officer: CBO, GC and Secretary | 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
Aaron Kantoff | director | C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH |
Sandeep Chidambar Kulkarni | director, officer: CEO | 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027 |
Kevin Bruce Johnson | officer: Chief Regulatory Officer | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Ryan F. Robinson | officer: Interim CFO | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Parvinder Thiara | director | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Susan Dana Jones | officer: Chief Technology Officer | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Suzanne Ildstad | director, 10 percent owner, officer: Chief Scientific Officer | C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481 |
Scott Requadt | director, officer: See Remarks | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Francois Nader | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
From GuruFocus
By Business Wire • 06-25-2023
By Value_Insider Value_Insider • 11-10-2022
By Value_Insider Value_Insider • 10-20-2022
By Marketwired • 06-26-2023
By sperokesalga sperokesalga • 02-16-2023
By PRNewswire • 08-22-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
By Marketwired • 06-22-2023
By Marketwired • 07-31-2023
By Value_Insider Value_Insider • 11-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.